NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced the filing with the U.S. Securities and ...

NEW YORK & ISTANBUL--(BUSINESS WIRE)--Cartesian Capital Group, a leading global private equity firm, announced today it has closed an equity investment in Turkey’s leading multi-brand food service ...

We obtain a Cartesian form of Putnam's inequality for doubly commuting hyponormal n-tuples, and we establish new relations between the Taylor and Xia spectra of such n-tuples.

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today ...

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic ...